365亿美元新“药王”诞生:代谢病主导时代开启

新快报
Feb 10

2025年全球“药王”权杖完成里程碑式交接。近日,全球各大药企发布2025年财报,礼来替尔泊肽以365.07亿美元销售额登顶,诺和诺德司美格鲁肽361亿美元紧随其后,连续两年夺冠的默沙东K药退居第三。两款GLP-1药物包揽冠亚军,标志着治疗时代的权力交接,从肿瘤免疫主导转向代谢疾病领域崛起,本质是不同治疗领域市场潜力的直接体现,全球医药产业格局迎来历史性重构。1决战2025年四季度,新“药王”实现...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10